http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2487708-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6736abd703229a7a6d2368657d571ed1 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-205 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate | 2012-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1500dd99712e5ab0fdbff54c057634a0 |
| publicationDate | 2013-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2487708-C1 |
| titleOfInvention | Method of treating parvoviral infection b19 in infants |
| abstract | FIELD: medicine. n SUBSTANCE: invention refers to medicine, namely paediatrics, and concerns treating parvoviral infection B19 in infants. That is ensured by the integrated therapy involving antiviral, immunocorrective effect, normalised liver function, hemoglobin, and metabolic processes. The therapy is prescribed as follows: viferon in suppositories administered rectally in a daily dose of 50 thousand units/kg daily for 10 days, then every other day for 3-5 months; ursofalk in the form of a suspension in a daily dose of 25 mg/kg per day administered for 3-4 months, no more than 250 mg/5 ml per day; folic acid 1 mg/day administered for 1 month repeated after 1 month; maltofer 10 drops administered 2 times a day for one month followed by 10 drops once a day for 2 months. After hemoglobin has been normalised, and cholestasis has been relieved, elkar is administered 10 drops 3 times a day for 1.5 months. n EFFECT: dose schedule of the drugs provides the effective treatment of parvoviral infection B19 in infants due to the complex ethiopathogenetic effect on the different links of the pathological process. n 2 ex |
| priorityDate | 2012-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 26.